---
title: "Teladoc Hold Rating Reaffirmed as 2026 Outlook Tightens and $6 DCF-Based Price Target Remains Unchanged"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285015852.md"
description: "TD Cowen analyst Charles Rhyee has reaffirmed a Hold rating on Teladoc (TDOC) stock, citing tightened 2026 guidance for revenue and adjusted EBITDA margins. He projects adjusted EBITDA of $279 million for 2026 and $289 million for 2027, with Integrated Care contributing $251 million and BetterHelp $28 million. Rhyee maintains a $6 price target, indicating limited upside. Evercore ISI also holds a $6 price target on the stock, reflecting a neutral stance."
datetime: "2026-05-04T01:45:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285015852.md)
  - [en](https://longbridge.com/en/news/285015852.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285015852.md)
---

# Teladoc Hold Rating Reaffirmed as 2026 Outlook Tightens and $6 DCF-Based Price Target Remains Unchanged

TD Cowen analyst Charles Rhyee has maintained their neutral stance on TDOC stock, giving a Hold rating on April 30.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Charles Rhyee has given his Hold rating due to a combination of factors, including Teladoc’s updated 1Q26 results and management’s decision to tighten 2026 guidance for revenue and adjusted EBITDA margins across both Integrated Care and BetterHelp. He now projects 2026 and 2027 adjusted EBITDA of $279 million and $289 million, respectively, signaling only modest improvement over time.

Within these forecasts, Rhyee estimates that Integrated Care will contribute $251 million of adjusted EBITDA in 2026, while BetterHelp will add $28 million, assuming insured revenue of $96 million, which sits comfortably inside management’s $90 million to $105 million range. Reflecting a balanced risk‑reward profile, he keeps his discounted cash flow–based price target unchanged at $6, implying limited upside and supporting a neutral Hold stance on the shares.

In another report released on April 30, Evercore ISI also maintained a Hold rating on the stock with a $6.00 price target.

### Related Stocks

- [TDOC.US](https://longbridge.com/en/quote/TDOC.US.md)
- [EDOC.US](https://longbridge.com/en/quote/EDOC.US.md)
- [FDHT.US](https://longbridge.com/en/quote/FDHT.US.md)
- [HEAL.US](https://longbridge.com/en/quote/HEAL.US.md)
- [EVR.US](https://longbridge.com/en/quote/EVR.US.md)

## Related News & Research

- [Teladoc Health Target of Unusually Large Options Trading (NYSE:TDOC)](https://longbridge.com/en/news/286944473.md)
- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)
- [Helium Evolution files Q1 2026 financial results.](https://longbridge.com/en/news/286968740.md)
- [Bureau Veritas: All resolutions passed at May 19, 2026 Shareholders' Meeting.](https://longbridge.com/en/news/286946080.md)
- [Correction: NextNRG to Host First Quarter 2026 Financial Results Conference Call on May 18, 2026 at 9:00 a.m. ET | NXXT Stock News](https://longbridge.com/en/news/286673001.md)